You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

PARPi

Showing 1 - 25 of 108
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Relapsed Ovarian Cancer Trial in Hangzhou (Secondary cytoreduction, Chemotherapy)

Recruiting
  • Relapsed Ovarian Cancer
  • Hangzhou, Zhejiang, China
    Women's Hospital, Zhejiang University School of Medicine
Nov 4, 2022

Ovarian Cancer Trial in Chongqing (fluzopanib and bevacizumab)

Recruiting
  • Ovarian Cancer
  • fluzopanib and bevacizumab
  • Chongqing, Chongqing, China
    Chongqing Cancer Hospital
Sep 19, 2022

Epithelial Ovarian Cancer Trial in Hangzhou (Pamiparib)

Not yet recruiting
  • Epithelial Ovarian Cancer
  • Hangzhou, Zhejiang, China
    Zhejiang Cancer Hospital
Aug 4, 2022

Ovarian Cancer Trial in Guangzhou (Pamiparib/Tamoxifen)

Not yet recruiting
  • Ovarian Cancer
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Centre
Dec 30, 2022

Recurrent Ovarian Cancer, Recurrent Fallopian Tube Cancer, Primary Peritoneal Cancer Trial (Niraparib, Dostarlimab)

Not yet recruiting
  • Recurrent Ovarian Cancer
  • +2 more
  • (no location specified)
Jul 26, 2022

Ovarian Cancer Recurrent Trial in Birmingham (M4344+Niraparib)

Not yet recruiting
  • Ovarian Cancer Recurrent
  • Birmingham, Alabama
    University of Alabama at Birmingham
Jan 5, 2023

Advanced Solid Tumors Trial in Huntersville, Cleveland (2X-121 and dovitinib)

Recruiting
  • Advanced Solid Tumors
  • 2X-121 and dovitinib
  • Huntersville, North Carolina
  • +1 more
Feb 1, 2023

PET and MRI Imaging of Brain Tumors Using [18F]PARPi

Recruiting
  • Brain Tumor
  • Brain Cancer
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Oct 21, 2021

Epithelial Ovarian Cancer Trial (Niraparib)

Not yet recruiting
  • Epithelial Ovarian Cancer
  • (no location specified)
May 19, 2022

Ovarian Cancer Recurrent Trial in Sutton, London (Niraparib oral capsule, SBRT)

Not yet recruiting
  • Ovarian Cancer Recurrent
  • Niraparib oral capsule
  • SBRT
  • Sutton, Surrey, United Kingdom
  • +1 more
Aug 10, 2023

Metastatic Castration-resistant Prostate Cancer Trial in Guangzhou

Recruiting
  • Metastatic Castration-resistant Prostate Cancer
    • Guangzhou, Guangdong, China
      Sun Yat-sen University Cancer Center
    Nov 1, 2021

    Head Neck Cancer Trial in New York ([18F]- PARPi, PET/CT Scans)

    Active, not recruiting
    • Head and Neck Cancer
    • [18F]- PARPi
    • PET/CT Scans
    • New York, New York
      Memorial Sloan Kettering Cancer Center
    Sep 14, 2021

    Tumors Trial in United States (GSK4524101, Niraparib)

    Not yet recruiting
    • Neoplasms
    • San Francisco, California
    • +5 more
    Oct 5, 2023

    Ovarian Cancer, Carcinosarcoma Trial (Pamiparib)

    Withdrawn
    • Ovarian Cancer
    • Carcinosarcoma
    • (no location specified)
    Aug 3, 2021

    Ovarian Cancer Trial in Tai'an (Bevacizumab, chemo, Fluzoparib)

    Recruiting
    • Ovarian Cancer
    • Tai'an, Shandong, China
      The Second Affiliated Hospital of Shandong First Medical Univers
    Dec 24, 2021

    Advanced Solid Tumors Trial in United States (KSQ-4279, KSQ-4279 will be combined in separate cohorts, including combination

    Recruiting
    • Advanced Solid Tumors
    • KSQ-4279
    • KSQ-4279 will be combined in separate cohorts, including combination with an oral PARPi (poly adenosine diphosphate-ribose polymerase inhibitor)
    • Boston, Massachusetts
    • +4 more
    Apr 5, 2022

    Ovarian Cancer Trial in Belgium, United Kingdom, United States (M6620, Avelumab, Carboplatin)

    Completed
    Has Results
    • Ovarian Cancer
    • Greenbrae, California
    • +12 more
    Oct 21, 2020

    Ovarian Carcinosarcoma, Endometrial Carcinosarcoma Trial in France (Niraparib, Niraparib + TSR-042 (Dostarlimab), Chemotherapy

    Recruiting
    • Ovarian Carcinosarcoma
    • Endometrial Carcinosarcoma
    • Angers, France
    • +19 more
    Feb 23, 2022

    Breast Cancer Trial in France (Main study:, Sub-study:)

    Recruiting
    • Breast Cancer
    • Main study:
    • Sub-study:
    • Bordeaux, France
    • +20 more
    Jan 2, 2023

    HRD and Resistance to PAPPi in EOC Patients

    Recruiting
    • Epithelial Ovarian Cancer
    • +6 more
    • Testing of homologous recombination deficiency
    • Beijing, Beijing, China
      Lei Li
    Mar 26, 2022

    Ovarian Cancer Trial in Worldwide (Olaparib, Ceralasertib, Placebo to match olaparib)

    Withdrawn
    • Ovarian Cancer
    • Anchorage, Alaska
    • +25 more
    Mar 9, 2021

    Pancytopenia Related to PARP Inhibitors (PancytoRIB)

    Completed
    • Cancer
    • PARP inhibitor
    • Caen, Basse Normandie, France
      Alexandre Joachim
    Sep 16, 2021

    Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma Trial in Shanghai (Primary debulking surgery,

    Not yet recruiting
    • Epithelial Ovarian Cancer
    • +2 more
    • Primary debulking surgery
    • +2 more
    • Shanghai, Shanghai, China
    • +3 more
    Aug 25, 2020

    Advanced Solid Tumor, Metastatic Solid Tumor Trial (ART6043, Olaparib, Talazoparib)

    Not yet recruiting
    • Advanced Solid Tumor
    • Metastatic Solid Tumor
    • (no location specified)
    Jun 1, 2023

    Efficacy and Safety Trial in Zhejiang (Arsenic trioxide Tablet +Fuzuloparib Capsules)

    Recruiting
    • Efficacy and Safety
    • Arsenic trioxide Tablet +Fuzuloparib Capsules
    • Zhejiang, Hangzhou, China
      Women's Hospital School Of Medicine Zhejiang University
    Jan 23, 2022